-
-
-
The use of 99mTc‐tetrofosmin in the characterisation of indeterminate renal masses: a pilot study BJU Int. (IF 3.7) Pub Date : 2024-09-23 Ergi Spiro, Salikh Murtazaliev, Alireza Amindarolzarbi, Sara Sheikhbahaei, Krystyna M. Jones, Mehrbod S. Javadi, Basil Kaufmann, Mohamad E. Allaf, Christian P. Pavlovich, Nirmish Singla, Lilja B. Solnes, Michael A. Gorin, Steven P. Rowe
-
Whole‐body MRI for staging prostate cancer: a narrative review BJU Int. (IF 3.7) Pub Date : 2024-09-23 Andrew M. Fang, Justin R. Gregg, Curtis Pettaway, Jingfei Ma, Janio Szklaruk, Tharakeswara K. Bathala, Devaki Shilpa S. Surasi, Brian F. Chapin
ObjectiveTo present a narrative review regarding the diagnostic accuracy of whole‐body magnetic resonance imaging (WBMRI) in staging patients with high‐risk prostate cancer (HRPCa) and compare it to established imaging modalities.MethodsA narrative review was carried out using PubMed using the following keywords: ‘whole body’, ‘magnetic resonance imaging’, ‘MRI’, ‘prostate cancer’, ‘risk stratification’
-
Urinary bladder transplantation in humans — current status and future perspectives Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-09-20 Michał C. Czarnogórski, Krzysztof Koper, Piotr Petrasz, Malte W. Vetterlein, Marta Pokrywczyńska, Kajetan Juszczak, Tomasz Drewa, Jan Adamowicz
-
A Patient-Prioritized Research Agenda for Clinical Trials in Kidney Stone Disease. J. Urol. (IF 5.9) Pub Date : 2024-09-20 Jonathan S Ellison,Kathryn E Flynn,Katherine Sheridan,Samantha Siodlarz,Jodi Antonelli,Christopher E Bayne,Hunter Beck,Christina Ching,Pankaj P Dangle,Casey Dauw,Carley Davis,Kim Hollander,Dirk Lange,Kristi Ouimet,Carswell Ouimet,Amy Y Pan,Kristina Penniston,Charles D Scales,Nayan Shah,Ryan Spiardi,Necole Streeper,Kristin Whitmore,Mike Witt,Liyun Zhang,Gregory E Tasian
PURPOSE To ensure that research on kidney stones provides meaningful impact for the kidney stone community, patients and caregivers should be engaged as stakeholders in clinical trial design, starting at study inception. This project aimed to elicit, refine, and prioritize research ideas from kidney stone stakeholders to develop a patient-centered research agenda for clinical trials. MATERIALS AND
-
Microwave vs radiofrequency ablation for small renal masses: perioperative and oncological outcomes BJU Int. (IF 3.7) Pub Date : 2024-09-18 Letizia Maria Ippolita Jannello, Franco Orsi, Stefano Luzzago, Giovanni Mauri, Francesco A. Mistretta, Mattia Luca Piccinelli, Chiara Vaccaro, Marco Tozzi, Daniele Maiettini, Gianluca Varano, Stefano Caramella, Paolo Della Vigna, Matteo Ferro, Guido Bonomo, Zhe Tian, Pierre I. Karakiewicz, Ottavio De Cobelli, Gennaro Musi
ObjectiveTo conduct a comprehensive comparison of microwave ablation (MWA) vs radiofrequency ablation (RFA) outcomes in the treatment of small renal masses (SRMs), specifically: TRIFECTA ([i] complete ablation, [ii] absence of Clavien–Dindo Grade ≥III complications, and [iii] absence of ≥30% decrease in estimated glomerular filtration rate) achievement, operative time (OT), and local recurrence rate
-
Reevaluating the Definition of "Clinically Significant" Prostate Cancer as Grade Groups 2-5: An Imperative for Improved Risk Stratification. J. Urol. (IF 5.9) Pub Date : 2024-09-17 Sigrid V Carlsson,Peter R Carroll,Freddie C Hamdy
-
Letter: miR-371a-3p Predicting Viable Tumor in Patients Undergoing Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer: The SWENOTECA-MIR Study. J. Urol. (IF 5.9) Pub Date : 2024-09-17 Klaus-Peter Dieckmann,Gazanfer Belge
-
Gut microbiota influence bladder tumour development Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-09-16 Louise Lloyd
New research, published in Nature, shows that gut microbiota carcinogen metabolism could contribute to chemical-induced carcinogenesis in the bladder. Chronic exposure to N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) induces bladder cancer in mouse models. Thus, the investigators used this model to examine the influence of gut microbiota on BBN-induced carcinogenesis and toxicokinetics.
-
Prescribing clinician specialty influences adherence to PrEP Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-09-13 Maria Chiara Masone
In a new study published in JAMA Internal Medicine, the association between patients abandoning or reversing the pre-exposure prophylaxis (PrEP) prescription and the specialty of the prescribing clinician has been assessed. Overall, 37,003 patients who were prescribed PrEP were assessed using pharmacy claims data. The majority of patients (67%) received their prescription from primary care practitioners
-
Intralesional heterogeneity on PSMA PET–CT predicts mCRPC outcomes Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-09-13 Maria Chiara Masone
Intra-tumour heterogeneity in patients with metastatic castration-resistant prostate cancer (mCRPC) poses a challenge to treatment, owing to variability in tumour growth and response to therapy. Currently available tools such as response evaluation criteria in solid tumors (RECIST) and circulating tumour DNA (ctDNA) are useful methods to measure patient response to treatment but do not enable the assessment
-
piRNA pathway disruption in human infertility Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-09-13 Maria Chiara Masone
PIWI-interacting RNAs (piRNAs) are crucial regulators of gene expression in male germ cells. In a study published in Nature Communications, the effect of disrupting piRNA biogenesis on human spermatogenesis was assessed. Analysis of exome data from >2,000 men with infertility led to the identification of biallelic variants in 14 genes related to the piRNA pathway in these men. These variants were associated
-
A wearable UBVM device to monitor bladder volume Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-09-13 Maria Chiara Masone
Measuring bladder volume is essential to assess bladder function for diagnosis and monitoring of lower urinary tract dysfunction, but currently available methods such as catheterization or ultrasonography are invasive and limited to the hospital setting. In a new study published in Nature Communications, a wireless and flexible ultrasonic bladder volume monitoring (UBVM) device was developed for continuous
-
Eleven-Year Experience With Midline Extraperitoneal Retroperitoneal Lymph Node Dissection for Germ Cell Tumors. J. Urol. (IF 5.9) Pub Date : 2024-09-13 Muhannad Alsyouf,Alireza Ghoreifi,Arman Ashrafi,Seyedeh-Sanam Ladi-Seyedian,Hamed Ahmadi,Madeleine Burg,Antoin Douglawi,Qi Nie,Ming Li,Sumeet Bhanvadia,Anne Schuckman,Hooman Djaladat,Siamak Daneshmand
PURPOSE A midline extraperitoneal approach for retroperitoneal lymph node dissection (EP-RPLND) has been associated with decreased morbidity compared to the transperitoneal approach. We aimed to review our 11-year experience in patients with germ cell tumors (GCTs) who underwent EP-RPLND at a single institution. MATERIALS AND METHODS All patients with GCT who underwent EP-RPLND between 2010 and 2021
-
Re: quality‐of‐life outcomes of the ROBOtic‐assisted vs conventional open partial nephrectomy (ROBOCOP) II trial BJU Int. (IF 3.7) Pub Date : 2024-09-13 Mithilesh Yadav, Sambit Tripathy, Kirti Singh, Swarnendu Mandal, Manoj Kumar Das, Kalandi Barik, Prasant Nayak
-
AI in prostate MRI: enhancing accuracy and reducing overdiagnosis Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-09-11 Baris Turkbey
Artificial intelligence can be leveraged to improve the detection of prostate cancer on magnetic resonance imaging; however, before this technology is implemented in clinical practice, further research is required.
-
Hypofractionated Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial Eur. Urol. (IF 25.3) Pub Date : 2024-09-12 Tamim Niazi, Abdenour Nabid, Talia Malagon, Steven Tisseverasinghe, Redouane Bettahar, Rafika Dahmane, Andre-Guy Martin, Marjory Jolicoeur, Michael Yassa, Maroie Barkati, Levon Igidbashian, Boris Bahoric, Robert Archambault, Hugo Villeneuve, Md Mohiuddin
Prostate Cancer Study 5 (PCS5) compared conventional fractionated radiotherapy (CFRT) with hypofractionated radiotherapy (HFRT) in high-risk prostate cancer (PCa) patients, hypothesizing similar toxicity and survival outcomes. This report presents the efficacy analysis.
-
Differences in mutations across tumour sizes in clear‐cell renal cell carcinoma BJU Int. (IF 3.7) Pub Date : 2024-09-12 Steven M. Monda, Benjamin W. Carney, Allison M. May, Shuchi Gulati, Simpa S. Salami, Thenappan Chandrasekar, Evan T. Keller, Nicolai A. Huebner, Ganesh S. Palapattu, Marc A. Dall'Era
ObjectiveTo assess the distribution of key mutations across tumour sizes in clear‐cell renal cell carcinoma (ccRCC), and secondarily to examine the prognostic impact of aggressive mutations in smaller ccRCCs.Patient and MethodsThe distribution of mutations (VHL, PBRM1, SETD2, BAP1 and CDKN2A loss) across tumour sizes was assessed in 1039 ccRCCs treated with nephrectomy in cohorts obtained from the
-
Robot‐assisted nephroureterectomy: surgical and mid‐term oncological outcomes in over 1100 patients (ROBUUST 2.0 collaborative group) BJU Int. (IF 3.7) Pub Date : 2024-09-12 Francesco Ditonno, Antonio Franco, Zhenjie Wu, Linhui Wang, Firas Abdollah, Giuseppe Simone, Andres F. Correa, Matteo Ferro, Sisto Perdonà, Daniele Amparore, Raj Bhanvadia, Stephan Brönimann, Dhruv Puri, Dinno F. Mendiola, Reuben Ben‐David, Sol C. Moon, Courtney Yong, Farshad S. Moghaddam, Alireza Ghoreifi, Eugenio Bologna, Leslie Claire Licari, Marco Finati, Gabriele Tuderti, Emma Helstrom, Marco
ObjectiveTo analyse surgical, functional, and mid‐term oncological outcomes of robot‐assisted nephroureterectomy (RANU) in a contemporary large multi‐institutional setting.Patients and MethodsData were retrieved from the ROBotic surgery for Upper tract Urothelial cancer STtudy (ROBUUST) 2.0 database, an international, multicentre registry encompassing data of patients with upper urinary tract urothelial
-
A decade long insight into patient views on kidney cancer care delivery BJU Int. (IF 3.7) Pub Date : 2024-09-12 Sabrina H. Rossi, Geraldine Fox, Malcolm Packer, Andrew Greaves, Maxine Tran, Natalie Charnley, Grenville Oades, Ekaterini Boleti, Grant D. Stewart
Patient and public involvement and engagement (PPIE) is crucial to ensure that patient care and research is relevant to patient needs and is more likely to have a positive impact. Indeed, previous research priority setting initiatives in kidney cancer, which have led to tangible research programmes, have actively involved patients and their carers [1]. A continued focus on the patients and the public
-
Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics BJU Int. (IF 3.7) Pub Date : 2024-09-12 Matthew J. Roberts, Nathan Papa, Hans Veerman, Katelijne de Bie, Andrew Morton, Anthony Franklin, Sheliyan Raveenthiran, William J. Yaxley, Maarten L. Donswijk, Henk G. van der Poel, Hemamali Samaratunga, David Wong, Nicholas Brown, Robert Parkinson, Troy Gianduzzo, Boon Kua, Geoffrey D. Coughlin, Daniela E. Oprea‐Lager, Louise Emmett, Pim J. van Leeuwen, John W. Yaxley, André N. Vis
ObjectivesTo construct and externally calibrate a predictive model for early biochemical recurrence (BCR) after radical prostatectomy (RP) incorporating clinical and modern imaging characteristics of the primary tumour.Patients and MethodsPatients who underwent RP following multiparametric magnetic resonance imaging, prostate biopsy and prostate‐specific membrane antigen‐positron emission tomography/computed
-
Cardiopulmonary exercise testing prior to radical cystectomy: a systematic review and meta‐analysis BJU Int. (IF 3.7) Pub Date : 2024-09-11 Allen Ao Guo, Kieran Zeng, Ymer Bushati, Paul Kim, Wenjie Zhong, Venu Chalasani, Matthew Winter
ObjectiveTo identify the association between cardiopulmonary exercise testing (CPET) and outcomes of radical cystectomy (RC), as RC is historically associated with high rates of short‐ and long‐term morbidity and mortality.MethodsThis quantitative systematic review and meta‐analysis was conducted in accordance with the Preferred Reporting Items for Systematic Review and Meta‐Analysis guidelines. An
-
The potential benefits of concomitant statins treatment in patients with non‐muscle‐invasive bladder cancer BJU Int. (IF 3.7) Pub Date : 2024-09-11 Kang Liu, Rossella Nicoletti, Hongda Zhao, Xuan Chen, Peter Ka‐Fung Chiu, Chi‐Fai Ng, Renate Pichler, Laura S. Mertens, Takafumi Yanagisawa, Luca Afferi, Andrea Mari, Satoshi Katayama, Juan Gomez Rivas, Riccardo Campi, Maria Carmen Mir, Michael Rink, Yair Lotan, Morgan Rouprêt, Shahrokh F. Shariat, Jeremy Yuen‐Chun Teoh
ObjectiveTo investigate the influence of statins on the survival outcomes of patients with non‐muscle‐invasive bladder cancer (NMIBC) treated with adjuvant intravesical bacille Calmette‐Guérin (BCG) immunotherapy.Patients and MethodsA retrospective cohort of consecutive patients with NMIBC who received intravesical BCG therapy from 2001 to 2020 and statins prescription were identified. Overall survival
-
Human sperm RNA in male infertility Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-09-10 Rossella Cannarella, Andrea Crafa, Roberto Curto, Laura M. Mongioì, Vincenzo Garofalo, Vittorio Cannarella, Rosita A. Condorelli, Sandro La Vignera, Aldo E. Calogero
-
Break Wave Lithotripsy for Urolithiasis: Results of the First-in-Human International Multi-Institutional Clinical Trial. J. Urol. (IF 5.9) Pub Date : 2024-09-10 Ben H Chew,Jonathan D Harper,Roger L Sur,Thomas Chi,Shubha De,Anne R Buckley,Ryan F Paterson,Victor K F Wong,Connor M Forbes,M Kennedy Hall,Ross Kessler,Seth K Bechis,Jason R Woo,Ralph C Wang,David B Bayne,Derek Bochinski,Trevor D Schuler,Tim A Wollin,Rahim Samji,Mathew D Sorensen
PURPOSE This study reports on a prospective, multicenter, single-arm, clinical trial utilizing the SonoMotion (San Mateo, California) Break Wave lithotripsy (BWL) device to fragment urinary stones. MATERIALS AND METHODS Patients with a urinary stone underwent a single treatment of 30 minutes and peak negative pressure of 4.5 to 8 MPa. Subjects were contacted and outcomes assessed at 7, 14, and 35 days
-
Letter: Mayo Clinic Validation of the AUA Risk Groups for Localized Renal Cell Carcinoma. J. Urol. (IF 5.9) Pub Date : 2024-09-10 Mattia Longoni,Giuseppe Rosiello,Alessandro Larcher,Francesco Montorsi,Umberto Capitanio
-
PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-09-09 Ailbhe Lawlor, Katharina Beyer, Beth Russell, Carl Steinbeisser, Anders Bjartell, Bertrand De Meulder, Muhammad Imran Omar, Tim Hulsen, John Butler, James N’Dow, Juan Gómez Rivas, Giorgio Gandaglia, Rossella Nicoletti, Vasileios Sakalis, Emma Jane Smith, Monika Maass, Jihong Zong, Louise Fullwood, Thomas Abbott, Azadeh Tafreshiha, Kishore Papineni, Robert Snijder, Denis Horgan, Sarah Seager, Susan
-
Non-coding transcriptome profiles in clear-cell renal cell carcinoma Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-09-06 Tereza Tesarova, Ondrej Fiala, Milan Hora, Radka Vaclavikova
-
Artificial intelligence in the management of prostate cancer Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-09-04 Raghav Khanna, Alejandro Granados Martinez, Nicholas Raison, Sebastien Ourselin, Alberto Briganti, Francesco Montorsi, Prokar Dasgupta
Artificial intelligence (AI) is transforming prostate cancer management from diagnosis to treatment. AI tools have been designed for the analysis of digitized histopathology and MRI scans, generation of synthetic CT scans and improvement of robotic surgical outcomes. This progress underscores the need for regulation and the development of safe, ethical and non-biased software.
-
Bridging the knowledge gap: past, present and future of antibiotic use for ureteral stents BJU Int. (IF 3.7) Pub Date : 2024-09-05 Jasper Cornette, Dirk Lange, Ben H. Chew, Thomas Tailly
ObjectiveTo evaluate the available literature on ureteric stent‐related infections, the use of antibiotics and bacterial colonisation to identify the current incidence of stent‐related infections, unveil knowledge gaps and generate potential hypotheses for future research.MethodsA literature review was conducted using PubMed, Cochrane and urological association websites identifying relevant English
-
Enzalutamide in Men With High-Risk Biochemically Recurrent Prostate Cancer: Rationale and Treatment Considerations From EMBARK. J. Urol. (IF 5.9) Pub Date : 2024-09-03 Neal D Shore,Ugo De Giorgi,Stephen J Freedland
-
A Multi-Institutional Study of Magnetic Resonance/Ultrasound Fusion-Guided Nanoparticle-Directed Focal Therapy for Prostate Ablation. J. Urol. (IF 5.9) Pub Date : 2024-09-03 Steven E Canfield,Arvin K George,Joshua S Jue,Sara C Lewis,Matthew S Davenport,Varaha S Tammisetti,Mahir Maruf,Leonardo D Borregalaes,Yara Kadria-Vili,Jon A Schwartz,Jennifer West,Naomi J Halas,Ardeshir R Rastinehad
PURPOSE Focal therapy aims to provide a durable oncologic treatment option for men with prostate cancer (PCa), while preserving their quality of life. Most focal therapy modalities rely on the direct tissue effect, resulting in a possible nontargeted approach to ablation. Here, we report the results of the first human feasibility trial utilizing nanoparticle-directed focal photothermal ablation for
-
Robotic appendiceal ureteric interposition or replacement: the surgical technique BJU Int. (IF 3.7) Pub Date : 2024-09-03 Silu Chen, Shubo Fan, Kunlin Yang, Zhihua Li, Wenzhi Gao, Xiang Wang, Zhenyu Li, Bing Wang, Chen Huang, Hongjian Zhu, Yaming Gu, Xuesong Li
-
Contemporary short‐term peri‐operative outcomes of open primary retroperitoneal lymph node dissection BJU Int. (IF 3.7) Pub Date : 2024-09-03 Jacob D. McFadden, Timothy A. Masterson, Clint Cary
ObjectivesTo provide current peri‐operative outcomes and short‐term complication rates for open primary retroperitoneal lymph node dissection (RPLND), with analysis of risk factors for complications.Patients and MethodsUsing the Indiana University Testicular Cancer database, we performed a retrospective analysis of all patients who underwent open primary RPLND over the study period (2018–2021). The
-
Cumulative re‐operation rates during follow‐up after hypospadias repair BJU Int. (IF 3.7) Pub Date : 2024-09-03 Annaleena Anttila, Tuija Lahdes‐Vasama, Niklas Pakkasjärvi, Seppo Taskinen
ObjectiveTo assess the cumulative rates of re‐operations after hypospadias repair and evaluate long‐term surgical outcomes at a tertiary paediatric urology centre.Patients and MethodsRetrospective analysis of 293 boys born between 1991 and 2003 undergoing hypospadias surgery was conducted. The study included 274 patients: 165 with distal, 34 with midshaft, and 75 with proximal hypospadias. Kaplan–Meier
-
Clinical Implications of Basic Research: Exploring the Transformative Potential of Spatial 'Omics in Uro-oncology Eur. Urol. (IF 25.3) Pub Date : 2024-09-02 Sandy Figiel, Anthony Bates, David A. Braun, Renu Eapen, Markus Eckstein, Brandon J. Manley, Matthew I. Milowsky, Tom J. Mitchell, Richard J. Bryant, John P. Sfakianos, Alastair D. Lamb
New spatial molecular technologies are poised to transform our understanding and treatment of urological cancers. By mapping the spatial molecular architecture of tumours, these platforms uncover the complex heterogeneity within and around individual malignancies, offering novel insights into disease development, progression, diagnosis, and treatment. They enable tracking of clonal phylogenetics in
-
Long-Term Outcomes of Recurrent Bulbar Urethral Stricture Treatment With the Optilume Drug-Coated Balloon: Five-Year Results From the ROBUST I Study. J. Urol. (IF 5.9) Pub Date : 2024-08-30 Jessica DeLong,Ramón Virasoro,Merycarla Pichardo,Rafael Estrella,Ramón Rodríguez Lay,Gustavo Espino,Sean Elliott
PURPOSE We report the 5-year study closeout results for the ROBUST I trial evaluating the safety and efficacy of the Optilume drug-coated balloon (DCB) for men with short, recurrent bulbar urethral strictures. MATERIALS AND METHODS Adult men with recurrent bulbar urethral strictures ≤ 2 cm long and lumen < 12F were included in the study and treated with the Optilume DCB. Outcome measures included symptom
-
Observational study on screen‐detected prostate cancer: case series of empirical clinical practice BJU Int. (IF 3.7) Pub Date : 2024-08-30 Takeshi Takahashi
-
Comparison of perioperative bleeding risk between direct oral anticoagulants in transurethral resection of prostate BJU Int. (IF 3.7) Pub Date : 2024-08-30 Lu Yu Kuo, Jenny Kuo, Joshua Silverman, Jason Jae Yeun Kim, Caitlin Letch, Scott McClintock
ObjectivesTo evaluate the perioperative morbidity and mortality associated with direct oral anticoagulants (DOACs) and warfarin for patients receiving transurethral resection of prostate (TURP).Patients and MethodsThis was a single‐centre, retrospective cohort analysis of patients who underwent TURP for benign prostate hyperplasia from April 2019 to December 2023. The primary objective was to evaluate
-
Variant genital gender‐affirming surgery: a systematic review BJU Int. (IF 3.7) Pub Date : 2024-08-30 Wietse Claeys, Dylan T. Wolff, Alexandra Zachou, Piet Hoebeke, Nicolaas Lumen, Anne‐Françoise Spinoit
ObjectiveTo review the available literature on variant genital gender‐affirming surgery (GGAS), including the reasons for performing it, the surgeries themselves and their outcomes.MethodsA systematic review on the performance of variant GGAS was conducted (International Prospective Register of Systematic Reviews [PROSPERO] identifier: CRD42022306684) researching PubMed, Embase, Web of Science and
-
Varying the intensity of cystoscopic surveillance for high‐risk non‐muscle‐invasive bladder cancer BJU Int. (IF 3.7) Pub Date : 2024-08-30 Zhuo Tony Su, Isabella S. Florissi, Katherine M. Mahon, Taibo Li, Michael E. Rezaee, Nirmish Singla, Sunil H. Patel, Jeffrey P. Townsend, Max R. Kates
ObjectivesTo compare the clinical, economic, and health utility outcomes associated with alternative cystoscopic surveillance regimens for high‐risk non‐muscle‐invasive bladder cancer (HRNMIBC).Patients and MethodsWe performed real‐world clinical data‐driven microsimulations of a hypothetical cohort of 100 000 patients diagnosed with HRNMIBC at age 70 years. The cohort was simulated to undergo alternative
-
Videourodynamics — role, benefits and optimal practice Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-08-29 Mikolaj Przydacz, Howard B. Goldman
-
The Importance of Being Grade 3: A Plea for a Three-tier Hybrid Classification System for Grade in Primary Non–muscle-invasive Bladder Cancer Eur. Urol. (IF 25.3) Pub Date : 2024-08-29 Irene J. Beijert, Oskar Hagberg, Truls Gårdmark, Lars Holmberg, Christel Häggström, Allan Johnston, Matthew Trail, Sami Hamid, Barend A. Dreyer, Luisa Padovani, Roberta Garau, Rami Hasan, Imran Ahmad, David Hendry, Eva M. Compérat, Maximilian Burger, Morgan Rouprêt, Paolo Gontero, Maria J. Ribal, Theo H. van der Kwast, Marko Babjuk, Richard J. Sylvester, Paramananthan Mariappan, Fredrik Liedberg, Bas
Grade is an important determinant of progression in non–muscle-invasive bladder cancer. Although the World Health Organization (WHO) 2004/2016 grading system is recommended, other systems such as WHO1973 and WHO1999 are still widely used. Recently, a hybrid (three-tier) system was proposed, separating WHO2004/2016 high grade (HG) into HG/grade 2 (G2) and HG/G3 while maintaining low grade. We assessed
-
Ureteroscopy vs laparoscopic ureterolithotomy: equal treatments? BJU Int. (IF 3.7) Pub Date : 2024-08-29 Øyvind Ulvik
In this issue of the BJUI, Torricelli et al. [1] report results from a randomised trial of participants who underwent treatment for large proximal ureteric stones with flexible ureteroscopy (URS) and holmium:yttrium-aluminium-garnet (Ho:YAG) lithotripsy or retroperitoneal laparoscopic ureterolithotomy (RLU). In total, 64 patients were included and randomised. Stone-free rates (SFRs) were 84.3% for
-
Urinary continence networks in Parkinson's disease: a resting state functional MRI study BJU Int. (IF 3.7) Pub Date : 2024-08-28 Holly A. Roy, Christopher Roy, Heidi Tempest, Alexander L. Green, Ricarda A.L. Menke
Lower urinary tract symptoms (LUTS) are a common feature of Parkinson's disease (PD), affecting up to 70% of patients [1] and significantly impairing quality of life. Ongoing use of continence aids also represents an economic burden. Deep brain stimulation (DBS) of the subthalamic nucleus (STN) has been shown to improve LUTS in PD [2] and to have a significant benefit regarding improvement of LUTS
-
The interplay between male fertility, mental health and sexual function Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-08-27 Vincent J. Straub, Melinda C. Mills
-
Quest for a genetic biomarker for sickle cell disease priapism: rationale, progress and implications Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-08-27 Oluwafolajimi Adesanya, Arthur L. Burnett
Currently, no consensus biomarker exists for predicting priapism associated with sickle cell disease. Biochemical and haematological parameters have been investigated, but they are limited by a lack of specificity and the need for pre-validated thresholds. Genetic biomarkers are a potential alternative for further consideration in future efforts.
-
Immune effects of α and β radionuclides in metastatic prostate cancer Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-08-27 Sapna Lunj, Tim Andrew Davies Smith, Kimberley Jayne Reeves, Fred Currell, Jamie Honeychurch, Peter Hoskin, Ananya Choudhury
-
Time to Change Our Mindset! Integrating Sustainability Into Urological Practice. J. Urol. (IF 5.9) Pub Date : 2024-08-27 Golena Fernandez Moncaleano,Nadya York,Khurshid R Ghani
-
Diagnostic Pathway Outcomes for Biparametric Magnetic Resonance Imaging-Targeted Lesions Using Cognitive Registration and Freehand Transperineal Prostate Biopsy in Biopsy-Naïve Men (CRAFT Single-Center Study). J. Urol. (IF 5.9) Pub Date : 2024-08-27 Samara Fleville,Carole O'Neill,Daniel Safar,Alex Macleod,Colin Mulholland,Filip Subin
PURPOSE Enhanced histological detection of clinically significant prostate cancer is the goal of the prebiopsy imaging pathway. Risk stratification at a prebiopsy meeting can facilitate optimization of lesion targeting. We aimed to evaluate the feasibility of cognitive registration, freehand transperineal prostate biopsy in a biopsy-naïve population following biparametric MRI for the detection of clinically
-
Inheritance patterns of lower urinary tract symptoms in adults: a systematic review BJU Int. (IF 3.7) Pub Date : 2024-08-27 Lorcan Moore, Nicholas Raison, Sachin Malde, Prokar Dasgupta, Arun Sahai
ObjectiveTo compile and evaluate the heritability and inheritance patterns of lower urinary tract symptoms (LUTS) in adult cohorts.MethodsSearches of five databases (PubMed, Embase, APA PsycInfo, Global Health, and OVID Medline) commenced on 6 July 2024, resulting in 736 articles retrieved after deduplication. Studies evaluating heritability patterns, gene frequencies, and familial aggregation of symptoms
-
Complete urethral preservation in robot‐assisted radical prostatectomy: step‐by‐step description of surgical technique BJU Int. (IF 3.7) Pub Date : 2024-08-27 Tarek Al‐Hammouri, Ricardo Almeida‐Magana, Lazaros Tzelves, Osama Al‐Bermani, Zafer Tandogdu, Jeremy Ockrim, Greg Shaw
Introduction Robot-assisted radical prostatectomy (RARP) is one of the treatment options for localised clinically significant prostate cancer [1]. However, postoperative urinary incontinence (UI) affects 4–31% of patients 12 months after surgery and is associated with a reduced quality of life [2]. Several surgical strategies have been described to reduce the incidence of UI, including anterior and
-
Outcomes of the Victo™ adjustable artificial urinary sphincter in the treatment of male incontinence BJU Int. (IF 3.7) Pub Date : 2024-08-27 Jan Krhut, Lucie Bartáková, Adéla Kondé, Radek Paus Sýkora, Tomáš Rychlý, Roman Zachoval
ObjectivesTo report the clinical outcomes of the Victo™ (Promedon, Cordoba, Argentina) adjustable artificial urinary sphincter (AUS) implantation in a cohort of patients with severe urinary incontinence (UI) after prostate surgery.Patients and MethodsThis study enrolled patients with UI following prostate surgery who underwent a Victo implantation between May 2018 and December 2023. Patients were prospectively
-
-
-
Utilising the differential renal length index in paediatric pyeloplasty: clinical applications and considerations BJU Int. (IF 3.7) Pub Date : 2024-08-27 Jiayi Li, Weiping Zhang
-
Advances in the detection and treatment of prostate cancer plus d‐mannose for the prevention of recurrent UTIs BJU Int. (IF 3.7) Pub Date : 2024-08-27
-
Salvage stereotactic ablative body radiotherapy after thermal ablation of primary kidney cancer BJU Int. (IF 3.7) Pub Date : 2024-08-27 Muhammad Ali, Young Suk Kwon, Kendrick Koo, Anna Bruynzeel, David Pryor, Daniel G. Schep, Michael Huo, Maggie Stein, Anand Swaminath, Raquibul Hannan, Shankar Siva
ObjectiveTo evaluate the effectiveness and safety of salvage stereotactic ablative body radiotherapy (SABR) for recurrent renal cell carcinoma (RCC) after thermal ablation (TA).Materials and MethodsThis study was a multi‐institutional retrospective analysis of patients with recurrent RCC following TA who received SABR between 2016 and 2020. The primary study outcome was freedom from local failure,
-
Response to utilising the differential renal length index in paediatric pyeloplasty: clinical applications and considerations BJU Int. (IF 3.7) Pub Date : 2024-08-27 Ketaki Gharpure, Abraham Cherian